Is Clinical Cancer Research a Good Journal? Fit Verdict
Clinical Cancer Research fit verdict: IF 10.2, AACR translational oncology. Here is when it fits and when Cancer Discovery or a disease-specific journal is smarter.
Research Scientist, Neuroscience & Cell Biology
Author context
Works across neuroscience and cell biology, with direct expertise in preparing manuscripts for PNAS, Nature Neuroscience, Neuron, eLife, and Nature Communications.
Journal fit
See whether this paper looks realistic for Clinical Cancer Research.
Run the Free Readiness Scan with Clinical Cancer Research as your target journal and see whether this paper looks like a realistic submission.
Clinical Cancer Research at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 10.2 puts Clinical Cancer Research in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~20-30% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Clinical Cancer Research takes ~~100-130 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read Clinical Cancer Research as a target
This page should help you decide whether Clinical Cancer Research belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | Clinical Cancer Research published by the American Association for Cancer Research is the premier journal. |
Editors prioritize | Clinical finding advancing cancer treatment or patient outcomes |
Think twice if | Basic biology without direct clinical relevance or patient outcome data |
Typical article types | Clinical Trial, Translational Research |
Clinical Cancer Research is the AACR's dedicated translational oncology journal, sitting at the bridge between basic cancer biology and clinical outcomes. With a 2024 impact factor of 10.2, it is a strong Q1 oncology title with a specific editorial identity: the work must connect mechanism to clinic. That makes it an excellent journal for the right paper and a frustrating target for the wrong one.
Key metrics
Metric | Value |
|---|---|
Impact Factor (2024) | 10.2 |
Publisher | American Association for Cancer Research (AACR) |
Acceptance rate | ~15-20% |
Open access | Hybrid (subscription with OA option) |
Category ranking | Q1, Oncology |
Typical content | Biomarker validation, translational studies, early-phase trials with correlative science |
What makes Clinical Cancer Research distinctive
The journal's editorial identity is translational oncology, not basic cancer biology, not purely clinical outcomes. This is the space between Cancer Research (which publishes mechanistic work without requiring clinical data) and Journal of Clinical Oncology (which publishes definitive clinical trial results). Clinical Cancer Research wants papers where the bench-to-bedside bridge is visible in the data, not just promised in the discussion.
In practice, this means the journal rewards biomarker validation studies, pharmacodynamic analyses from early-phase trials, resistance mechanism work with patient tumor data, and studies where molecular findings directly inform treatment stratification. The common rejection pattern is a paper that is really basic cancer biology with a paragraph of clinical speculation added at the end.
How Clinical Cancer Research compares
Journal | IF (2024) | Publisher | Best for |
|---|---|---|---|
Journal of Clinical Oncology | 41.9 | ASCO | Definitive clinical trials, practice-changing outcomes |
Cancer Discovery | 33.3 | AACR | High-impact cancer biology and therapeutic vulnerability |
Cancer Research | 16.6 | AACR | Broad cancer biology including basic mechanism |
Clinical Cancer Research | 10.2 | AACR | Translational oncology, biomarker correlatives |
Molecular Cancer Therapeutics | 5.6 | AACR | Preclinical drug development and therapeutic targeting |
The AACR journal hierarchy matters here. Cancer Discovery is the highest-impact AACR title and publishes broadly across cancer biology with an emphasis on discovery. Cancer Research is the broadest AACR journal and accommodates purely basic work. Clinical Cancer Research occupies the translational middle ground. Molecular Cancer Therapeutics is narrower and more preclinical.
Against JCO, the distinction is straightforward: JCO publishes practice-changing clinical evidence. Clinical Cancer Research publishes the translational science that feeds into (or emerges from) clinical trials. If your paper reports a randomized trial with a primary clinical endpoint, JCO is the natural home. If your paper validates a biomarker in a clinical cohort or reports correlative science from an early-phase trial, Clinical Cancer Research is likely the right call.
Submit if
- Your paper has patient-derived data or clinical specimens, not just cell lines and mouse models
- The translational bridge is visible in the figures, not rescued in the discussion
- You are reporting biomarker validation, therapeutic response correlates, or resistance mechanisms with clinical relevance
- The study design supports the translational claim (not just a cell line paper with a single TMA slide)
- Early-phase trial results include molecular correlatives that inform treatment logic
Journal fit
See whether this paper looks realistic for Clinical Cancer Research.
Run the scan with Clinical Cancer Research as the target. Get a manuscript-specific fit signal before you commit.
Think twice if
- The paper is primarily mechanistic cancer biology without patient-facing data
- Clinical relevance appears only in the discussion as speculation
- The model systems are too far from human disease to support translational framing
- A basic-science journal like Cancer Research would describe the work more honestly
- The paper is really a clinical outcomes study that belongs at JCO or a disease-specific clinical journal
Frequently asked questions
How does Clinical Cancer Research handle biomarker papers?
Biomarker work is core to the journal's identity. But the bar is analytical and clinical validation, not just discovery. A paper reporting a novel biomarker with only cell line data will struggle. Add clinical cohort validation and the fit improves dramatically.
Is Clinical Cancer Research good for early-career researchers?
Yes, if the paper is genuinely translational. The journal does not require senior authorship from famous labs. What it requires is data that bridges mechanism and clinic. Early-career researchers with access to clinical specimens or trial correlatives can compete.
How long does review take?
Expect 4-8 weeks for first decision. AACR journals generally provide relatively timely editorial turnaround compared to some society journals.
Can I submit purely computational translational work?
Computational papers can work if they validate predictions with clinical data. A purely in silico analysis predicting drug response without any clinical or experimental validation will be a weak fit.
Bottom line
Clinical Cancer Research is a strong translational oncology journal with clear editorial standards. The fit test is simple: can a reader see the mechanism-to-clinic connection in your data, or does that connection only appear in your interpretation? If the translational bridge is in the evidence, this is a natural target. If you are relying on framing to create translational relevance, Cancer Research or a disease-specific journal will serve the paper better.
Not sure if your translational framing is strong enough? A CCR submission readiness check can help you assess fit and positioning before you submit.
Before you submit
A CCR submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.
What Clinical Cancer Research actually publishes
Clinical Cancer Research (AACR, IF ~10) is the only AACR journal with clinical research as its sole purview. It bridges late preclinical development to clinical validation, phase I/II trials, biomarker validation, drug resistance mechanisms with clinical data, and personalized medicine approaches.
CCR does not publish basic cancer biology without clinical connection (that belongs at Cancer Research). It does not accept epidemiology without mechanism. The highest editorial priority goes to translational studies involving new targets or strong mechanism-based hypotheses tested in patients.
CCR vs Cancer Research: if the paper's lead story is about a molecular mechanism, Cancer Research. If it's about testing that mechanism in patients, Clinical Cancer Research. The distinction is translational direction: bench-to-bedside (CCR) vs bench-focused (Cancer Research).
A CCR desk-rejection risk check scores fit against the journal's editorial bar.
Frequently asked questions
Yes. Clinical Cancer Research is a leading AACR journal with a 2024 impact factor of 10.2 and Q1 ranking in Oncology. It is the primary AACR venue for translational cancer research that bridges laboratory findings and clinical application.
Clinical Cancer Research has an acceptance rate of approximately 15-20%. The journal requires manuscripts to demonstrate genuine translational consequence, a visible bridge between mechanism and clinical decision-making.
Yes. Clinical Cancer Research uses rigorous peer review managed by the American Association for Cancer Research. Papers are evaluated by experts in translational oncology, biomarker science, and clinical cancer research.
Both are AACR journals. Cancer Research (IF 11.6) publishes broader cancer biology including basic mechanism work. Clinical Cancer Research (IF 10.2) specifically requires a translational or clinical anchor, biomarker validation, therapeutic response data, or early-phase trial results. If your paper is primarily mechanistic without patient-facing data, Cancer Research is the better fit.
Sources
- 1. Clinical Cancer Research journal page, AACR.
- 2. Clinical Cancer Research instructions for authors, AACR.
- 3. Clarivate Journal Citation Reports (released June 2025).
Final step
See whether this paper fits Clinical Cancer Research.
Run the Free Readiness Scan with Clinical Cancer Research as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Clinical Cancer Research Submission Guide: Requirements & Timeline
- How to Avoid Desk Rejection at Clinical Cancer Research
- Clinical Cancer Research Review Time: What Authors Can Actually Expect
- Clinical Cancer Research Acceptance Rate: What Authors Can Use
- Clinical Cancer Research Impact Factor 2026: 10.2, Q1, Rank 29/326
- BMJ vs Clinical Cancer Research: Best Fit for Your Paper
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits Clinical Cancer Research.
Anthropic Privacy Partner. Zero-retention manuscript processing.